Incannex Healthcare (IXHL) Expected to Announce Earnings on Thursday

Incannex Healthcare (NASDAQ:IXHL) is projected to issue its Q3 2026 resultson Thursday, May 14th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $0.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Incannex Healthcare (NASDAQ:IXHL) last posted its quarterly earnings data on Friday, February 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). On average, analysts expect Incannex Healthcare to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Incannex Healthcare Stock Up 3.4%

IXHL opened at $4.91 on Thursday. The business has a fifty day moving average of $3.74 and a 200 day moving average of $8.25. Incannex Healthcare has a 52-week low of $2.40 and a 52-week high of $49.80. The stock has a market cap of $58.59 million, a P/E ratio of -0.58 and a beta of 7.22.

Institutional Investors Weigh In On Incannex Healthcare

Several hedge funds have recently made changes to their positions in IXHL. Virtu Financial LLC purchased a new stake in shares of Incannex Healthcare in the 3rd quarter worth $187,000. LPL Financial LLC lifted its holdings in shares of Incannex Healthcare by 639.1% in the 4th quarter. LPL Financial LLC now owns 335,373 shares of the company’s stock worth $120,000 after buying an additional 290,000 shares during the period. Jane Street Group LLC lifted its holdings in shares of Incannex Healthcare by 547.4% in the 4th quarter. Jane Street Group LLC now owns 1,491,835 shares of the company’s stock worth $534,000 after buying an additional 1,261,385 shares during the period. Finally, Arete Wealth Advisors LLC lifted its holdings in shares of Incannex Healthcare by 88.7% in the 4th quarter. Arete Wealth Advisors LLC now owns 2,223,450 shares of the company’s stock worth $796,000 after buying an additional 1,044,862 shares during the period. 0.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IXHL has been the subject of a number of recent analyst reports. Wall Street Zen cut Incannex Healthcare from a “hold” rating to a “sell” rating in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Incannex Healthcare in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Incannex Healthcare currently has an average rating of “Sell”.

About Incannex Healthcare

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.